EP0180899B1 - Séquences à réplication autonome pour des souches de levure du genre Pichia - Google Patents

Séquences à réplication autonome pour des souches de levure du genre Pichia Download PDF

Info

Publication number
EP0180899B1
EP0180899B1 EP85113735A EP85113735A EP0180899B1 EP 0180899 B1 EP0180899 B1 EP 0180899B1 EP 85113735 A EP85113735 A EP 85113735A EP 85113735 A EP85113735 A EP 85113735A EP 0180899 B1 EP0180899 B1 EP 0180899B1
Authority
EP
European Patent Office
Prior art keywords
plasmid
pichia pastoris
dna
drawings
restriction map
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP85113735A
Other languages
German (de)
English (en)
Other versions
EP0180899A2 (fr
EP0180899A3 (en
Inventor
James Michael Cregg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc Te Tucson
Original Assignee
Phillips Petroleum Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phillips Petroleum Co filed Critical Phillips Petroleum Co
Priority to AT85113735T priority Critical patent/ATE71660T1/de
Publication of EP0180899A2 publication Critical patent/EP0180899A2/fr
Publication of EP0180899A3 publication Critical patent/EP0180899A3/en
Application granted granted Critical
Publication of EP0180899B1 publication Critical patent/EP0180899B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y10S435/938—Pichia

Definitions

  • This invention relates to the field of recombinant DNA technology.
  • the invention relates to DNA fragments which are maintained as extrachromosomal elements in a host of the genus Pichia .
  • the invention relates to expression vectors which incorporate the above-described DNA fragments.
  • the invention relates to novel microorganisms transformed with the above-described expression vectors.
  • the invention relates to a process for isolating the novel DNA fragments of the invention.
  • the basic techniques employed in the field of recombinant DNA technology are known by those of skill in the art.
  • the elements desirably present in order for a host microorganism to be useful for the practice of recombinant DNA technology include, but are not limited to:
  • a basic element employed in recombinant DNA technology is the plasmid, which is extrachromosomal, double-stranded DNA found in some microorganisms. Where plasmids have been found to naturally occur in microorganisms, they are often found to occur in multiple copies per cell. In addition to naturally occurring plasmids, a variety of man-made plasmids, or hybrid vectors, have been prepared. Included in the information encoded in plasmid DNA is that required to reproduce the plasmid in daughter cells, i.e., an autonomous replication sequence. One or more phenotypic selection characteristics must also be included in the information encoded in the plasmid DNA. The phenotypic selection characteristics permit clones of the host cell containing the plasmid of interest to be recognized and selected by preferential growth of the cells in selective media.
  • plasmids The utility of plasmids lies in the fact that they can be specifically cleaved by one or another restriction endonuclease or restriction enzyme, each of which recognizes a specific, unique site on the plasmid DNA. Thereafter, homologous genes, heterologous genes, i.e., genes derived from organisms other than the host, or gene fragments may be inserted into the plasmid by endwise joining of the cleaved plasmid and desired genetic material at the cleavage site or at reconstructed ends adjacent to the cleavage site. The resulting recombined DNA material can be referred to as a hybrid vector.
  • DNA recombination is performed outside the host microorganism.
  • the resulting hybrid vector can be introduced into the host microorganism by a process known as transformation. By growing the transformed microorganism, large quantities of the hybrid vector can be obtained.
  • the resulting hybrid vector can be used to direct the production of the polypeptide sequence for which the inserted gene codes. The production of polypeptide in this fashion is referred to as gene expression.
  • E. coli may prove to be unsuitable as a host.
  • E. coli contains a number of toxic pyrogenic factors that must be eliminated from any polypeptide useful as a pharmaceutical product.
  • the efficiency with which this purification can be achieved will, of course, vary with the particular polypeptide.
  • the proteolytic activities of E. coli can seriously limit yields of some useful products.
  • Yeast has been employed in large scale fermentations for centuries, as compared to the relatively recent advent of large scale E. coli fermentations. Yeasts can generally be grown to higher cell densities than bacteria and are readily adaptable to continuous fermentation processing. In fact, growth of yeast such as Pichia pastoris to ultra-high cell densities, i.e., cell densities in excess of 100 g/L, is disclosed by Wegner in U.S. 4,414,329 (assigned to Phillips Petroleum Co.).
  • yeast hosts include the fact that many critical functions of the organism, e.g., oxidative phosphorylation, are located within organelles, and hence not exposed to the possible deleterious effects of the organism's production of polypeptides foreign to the wild-type host cells.
  • yeast may prove capable of glycosylating expressed polypeptide products where such glycosylation is important to the bioactivity of the polypeptide product. It is also possible that as a eukaryotic organism, yeast will exhibit the same codon preferences as higher organisms, thus tending toward more efficient production of expression products from mammalian genes or from complementary DNA (cDNA) obtained by reverse transcription from, for example, mammalian mRNA.
  • cDNA complementary DNA
  • An object of the invention is therefore novel autonomous replication sequences (ARS) which maintain plasmids as extrachromosomal elements in multi-copies per cell in hosts of the genus Pichia .
  • ARS autonomous replication sequences
  • Another object of the invention is novel vectors capable of maintenance as extrachromosomal elements in hosts of the genus Pichia.
  • Yet another object of the invention is novel yeast strains of the genus Pichia.
  • restriction sites employed for the manipulation of DNA but which are destroyed upon ligation are indicated by enclosing the abbreviation for the destroyed site in parenthesis. Restriction sites which are predicted by nucleic acid sequence data but have not been verified by actual restriction enzyme treatment are indicated by flagging the designated restriction site with an asterisk.
  • novel DNA fragments comprising autonomous replication sequences which maintain plasmids as extrachromosomal elements in hosts of the genus Pichia.
  • Host organisms contemplated to be useful for the practice of the present invention include the various species of the genus Pichia.
  • One class of useful hosts are auxotrophic mutants, i.e., mutant strains which require supplementation with one or more amino acids, vitamins or other nutrients in order to grow. Transformation of such a mutant can be readily selected by employing, as part of the recombinant DNA material used to transform the mutant host, DNA sequences which code for the production of the missing gene product.
  • An especially preferred host yeast strain is the mutant Pichia pastoris GS115, which is a mutant defective in the ability to produce histidine, and has been identified as having the mutant genotype his 4.
  • GS115 was derived by mutagenesis of Pichia pastoris NRRL Y-11430 and has been deposited with the Northern Regional Research Center of the United States Department of Agriculture in Peoria, Illinois, in order to ensure free access of the host to the public upon issuance of this application as a patent.
  • Pichia pastoris GS115 has been assigned the accession number NRRL Y-15851, as of August 31, 1984. This particular host is useful because it is an auxotrophic mutant deficient in the histidine pathway.
  • Pichia pastoris NRRL Y-15851 has been identified as a mutant defective in the production of histidinol dehydrogenase. This identification was accomplished by measuring the reduction of nicotinamide adenine dinucleotide (NAD) by a protein extract from cells of NRRL Y-15851 in the presence of the histidinol dehydrogenase substrate, histidinol.
  • NAD nicotinamide adenine dinucleotide
  • the defect in NRRL Y-15851 is referred to as a his 4C mutation.
  • the HIS4 gene was isolated from the strain P. pastoris NRRL Y-11430 by partial digestion of total chromosomal DNA with Sau 3A followed by centrifugation through sucrose gradients. Fragments of 5 to 20 kbp were cloned into the Bam HI cleavage site of the S. cerevisiae-E. coli shuttle vector YEp13 (ATCC 37115; Figure 3) and transformed into E. coli. Approximately 50,000 colonies were selected and combined, then total plasmid DNA extracted. Spheroplasts of S.
  • yeast DNA was extracted from 20 of the His+ colonies and transformed back into E. coli. Seventeen of the yeast DNA preparations produced ampicillin resistant colonies.
  • HIS4-containing plasmid contains pBR325 sequences, including functional chloramphenicol and ampicillin resistance genes, as well as the Pichia HIS4 gene.
  • GS115 (NRRL Y-15851) can be transformed by enzymatic digestion of the cell walls to give spheroplasts; the spheroplasts are then mixed with the transforming recombinant DNA material and incubated in the presence of calcium ions and polyethylene glycol, then regenerated in selective growth medium deficient in histidine.
  • the transforming DNA includes the HIS4 gene in which the host strain is deficient, thus only transformed cells survive on the selective growth medium employed.
  • the vectors of the present invention contain Pichia -derived autonomous replication sequences (PARSs), which enhance both the transformation frequency of GS115 (NRRL Y-15851) and the maintenance of the vectors as stable extrachromosomal elements in yeasts of the genus Pichia.
  • PARSs Pichia -derived autonomous replication sequences
  • These autonomous replication sequences are useful because known yeast ARS elements isolated from S. cerevisiae do not function in hosts of the genus Pichia.
  • Plasmid DNA from Pichia pastoris NRRL Y-15851 was partially digested with Taq I and 5 to 10 kbp fragments were isolated and cloned into the unique Cla I site of pYJ8 ⁇ Cla (See Figure 5). Plasmid DNA was amplified in E. coli, recovered and used to transform Pichia pastoris NRRL Y-15851. Plasmid DNA was then recovered from about 10,000 His+ Pichia colonies and used to retransform E. coli. Plasmids from about 10,000 ampicillin resistant E. coli colonies were isolated and then transformed back into P. pastoris NRRL Y-15851 (GS115; his 4).
  • Plasmid pYJ30 is shown in detail in Figure 7 while plasmid pYJ32 is similarly depicted in Figure 8.
  • the plasmids, transformed into an E. coli host have been deposited with the Northern Regional Research Center of the U.S. Department of Agriculture, Peoria, Illinois, to insure free access to the public upon issuance of this application as a patent.
  • the deposited strains have been assigned accession numbers as follows: Plasmid Host Strain NRRL Accession No. pYJ30 LE392 NRRL B-15890 pYJ32 LE392 NRRL B-15891
  • the autonomous replication sequences of the invention can conveniently be recovered from pYJ30 and pYJ32, respectively, by treating the plasmids with the restriction enzymes Eco RI and Hin dIII.
  • the desired ARS element is then obtained with about 23 extra base pairs at the 5' end (adjacent the R1 site) and with about 5 extra base pairs at the 3' end (adjacent the H3 site).
  • the PARS1 and PARS2 inserts can, of course, also be recovered from pYJ30 and pYJ32 by treatment of the plasmids with a variety of other restriction enzymes, as readily recognized by those of skill in the art upon inspection of the restriction maps provided in Figures 7 and 8.
  • the PARS1 and PARS2 inserts have been characterized by restriction enzyme mapping. These two DNA fragments are shown in Figures 1 and 2, respectively.
  • the nucleotide sequence for PARS1 has been determined to be:
  • the nucleotide sequence for PARS2 has been determined to be:
  • An average plasmid copy number per Pichia pastoris cell was derived from the ratio of the amount of the genomic copy of the Pichia HIS4 gene to that of plasmid-borne HIS4 gene.
  • the average number of copies of plasmid DNA containing the Pichia HIS4 gene relative to the number of copies of Pichia chromosomal HIS4 gene was about 10-15. It is recognized by those of skill in the art that the values for copy number derived as described herein represent minimum estimates for the number of plasmid copies per cell.
  • DNA sequences which have autonomous replication activity in a host of the genus Pichia can be isolated by transforming the Pichia host with a library of DNA fragments constructed in a vector which contains, among other DNA sequences, a marker gene, but does not contain any DNA sequences with ARS activity in Pichia.
  • the marker gene employed will confer a selectable phenotype upon the host yeast strain.
  • the frequency of transformation of the host strain with the vector will be increased by one or more orders of magnitude when DNA sequences with ARS activity are present in the vector compared to the frequency of transformation with unmodified vector.
  • selection and isolation of transformed host will provide organisms carrying plasmids with inserted DNA sequences which have ARS activity. In this fashion, DNA sequences from any source which have ARS activity in Pichia can be readily isolated.
  • Centrifugation is carried out for a period of time and at a spin rate sufficient to provide a clear supernatant. Generally, centrifugation of yeast cells is carried out at at least 1500 g for at least 5 minutes.
  • Nucleic acid extractions with phenol/chloroform/isoamyl alcohol involve contacting the nucleic acid containing solution with an equal volume of a 50:48:2 ratio by volume mixture of phenol, chloroform and isoamyl alcohol, respectively. Extractions with chloroform/isoamyl alcohol involve contacting the solution to be treated with an equal volume of 48:2 ratio by volume mixture of chloroform and isoamyl alcohol.
  • Ethanol precipitation of nucleic acids involves first adjusting the salt content of the nucleic acid-containing solution, if necessary, then contacting the solution with two volumes of cold ethanol, then collecting the precipitate by centrifugation.
  • strains employed include:
  • pYA2 ( Figure 9) which consists of the S. cerevisiae HIS4 gene on a 9.3 kb Pst I fragment inserted at the Pst I site of pBR325 was the source of the S. cerevisiae HIS4 gene fragments and has been deposited in an E. coli host and is available to the public as NRRL B-15874.
  • IMG a minimal medium, consists of the following:
  • E. coli was cultured in either LB medium or 2B medium (0.2% NH4PO4, 1.2% Na2HPO4, 0.013% MgSO4 ⁇ 7H2O, 0.074% CaCl2 ⁇ 2H2O, 1 ⁇ g/mL thiamine and 0.4% dextrose) supplemented with 100 ⁇ g/mL tryptophan, and 0.2% Casamino acids.
  • Both Pichia pastoris and S. cerevisiae DNA preparations were carried out by growing yeast cells in 100 mL of minimal medium until A600 equals 1-2 and then harvesting the cells by centrifugation at 2,000 g for 5 minutes. The cells were washed once in H2O, once in SED, once in 1 M sorbitol and then suspended in 5 mL of 0.1 M Tris-HCl (pH 7.0) which is 1 M in sorbitol. The cells were mixed with 50-100 ⁇ L of a 4 mg/mL solution of Zymolase 60,000 (Miles Laboratories) and incubated at 30°C for 1 hour to digest the cell walls.
  • the spheroplast preparation was then centrifuged at 1000 g for 5-10 minutes and suspended in Lysis buffer (0.1% SDS, 10 mM Tris-HCl, (pH 7.4), 5 mM EDTA and 50 mM NaCl). Proteinase K (Boehringer Mannheim) and RNase A (Sigma) were each added to 100 ⁇ g/mL and the mixtures incubated at 37°C for 30 minutes. DNA was deproteinized by gently mixing the preparation with an equal volume of chloroform containing isoamyl alcohol and the phases were separated by centrifugation at 12,000 g for 20 minutes.
  • Lysis buffer 0.1% SDS, 10 mM Tris-HCl, (pH 7.4), 5 mM EDTA and 50 mM NaCl.
  • Proteinase K Boehringer Mannheim
  • RNase A Sigma
  • the upper (aqueous) phase was drawn off into a fresh tube and extracted with an equal volume of phenol/ chloroform/isoamyl alcohol.
  • the phases were separated as before and the top phase placed in a tube containing 2-3 volumes of cold 100% ethanol.
  • the sample was gently mixed and DNA was collected by spooling onto a plastic rod.
  • the DNA was immediately dissolved in 1 mL of TE buffer and dialyzed overnight at 4°C against 100 volumes TE buffer.
  • the samples were mixed with 100 ⁇ L of 5 M potassium acetate, held in an ice bath for 15 minutes and centrifuged for 5 minutes.
  • the supernatants were decanted into a fresh microfuge tube containing 1 mL of 100% ethanol, mixed and immediately centrifuged for 10 seconds. Finally, the DNA pellets were air dried for 10-15 minutes and dissolved in 50 ⁇ L of TE buffer.
  • E. coli cultures for large scale (0.5-1 L) plasmid preparations were grown at 37°C with shaking in 2B medium supplemented as described above and with the appropriate antibiotic.
  • cultures were grown to an A550 of about 0.7 at which time sufficient chloramphenicol was added to give a concentration of 100 ⁇ g/mL and cells harvested approximately 15 hours later.
  • Strains which contained pBR325 derived plasmids were inoculated into the supplemented 2B medium at a starting A550 of about 0.01-0.05 and incubated with shaking at 37°C for 20-24 hours before harvesting. Plasmids were isolated by the alkaline lysis method described by Birnboim and Doly (1979).
  • Plasmids were isolated by the alkaline lysis method described by Birnboim and Doly (1979).
  • Restriction enzymes were obtained from New England Biolabs and Bethesda Research Laboratories and digestions were performed by routine techniques. Restriction mappings were carried out by comparing parallel digestions of plasmids with and without insert DNA. Restriction fragments were purified by electroelution from agarose gels into Whatman 3 MM paper strips backed by dialysis tubing. The fragments were recovered from the paper and tubing by 3-4 washings with 0.1-0.2 mL volumes of a solution which contained 0.1 M NaCl, 50 m M Tris-HCl (pH 8.0) and 1 m M EDTA. Finally, the fragments were extracted with phenol/chloroform/isoamyl alcohol, precipitated with ethanol and redissolved in a small volume of TE buffer.
  • Pichia pastoris DNA-pYJ8 ⁇ Cla library construction 50 ⁇ g of pYJ8 ⁇ Cla was digested to completion with Cla I and treated with calf intestinal alkaline phosphatase to remove the terminal 5' phosphate from the DNA.
  • a 100 ⁇ g aliquot of DNA from Pichia pastoris NRRL Y-15851 was partially digested with 20 units of Taq I by incubation for 5 minutes at 65°C in a total volume of 1 mL. Fragments of 5 to 10 kbp were size selected by electroelution from a 0.5% agarose gel (See Example II, Section E).
  • T4 DNA ligase (Bethesda Research Laboratories) in a total volume of 200 ⁇ L and incubated overnight at 4°C.
  • the ligated DNAs were transformed into E. coli by adding the entire ligation reaction mix to 2 mL of competent E. coli 848 cells and incubating for 15 minutes at 0°C. The mixture was warmed to 37°C for 5 minutes after which time 40 mL of LB medium was added and the 37°C incubation continued for another 1 hour. Ampicillin was then added to give a total concentration of 100 ⁇ g/mL and the incubation continued for a second hour.
  • the cells were centrifuged for 10 minutes at 3,000 g, resuspended in 1 mL of fresh LB medium and spread in equal aliquots on 10 LB agar plates containing 100 ⁇ g/mL of ampicillin. The approximately 10,000 colonies which resulted were scraped from the plates and a portion of the cells was inoculated into 500 mL of the supplemented 2B medium at a starting A550 of about 0.1. The culture was grown and plasmid was extracted as described above.
  • Hybridizations were carried out by the method described by Southern (1975). For transfer of large or supercoiled DNA molecules to nitrocellulose, DNA was first partially hydrolyzed by soaking agarose gels in 0.25 M HCl for 10 minutes prior to alkali denaturation. The hybridization of labelled fragments from the S. cerevisiae HIS4 gene to Pichia pastoris DNA was performed in the presence of 50% formamide, 6x SSC, 5x Denhardt's, 0.1% SDS, 1 m M EDTA, and 100 ⁇ g/mL denatured herring sperm DNA at 42°C. Post-hybridization washes were in 2x SSC, 1 m M EDTA, 0.1% SDS and 1.0% sodium pyrophosphate at 55°C.
  • DNA sequencing was by the dideoxynucleotide chain termination method of Sanger et al (1980).
  • Two plasmids, pYA63, containing PARS1 and pYA90 containing PARS2 were selected for further analysis. Both of these plasmids transformed Pichia pastoris NRRL Y-15851 (GS115) at very high frequency, were maintained as autonomous elements and each contained a novel fragment of P. pastoris DNA.
  • Pichia ARS-containing plasmids The ability of Pichia ARS-containing plasmids to be maintained as autonomous elements in Pichia pastoris cells was determined as follows: A transformant colony was picked from the regeneration agar plate and streaked onto an SD medium agar plate and inoculated into liquid IMG medium. The SD plate was incubated at 30°C for 3 days after which time a single colony was picked from this plate, streaked onto a second SD plate and inoculated into a second flask of IMG medium. This process was repeated a third time. The 3 IMG cultures were grown at 30°C with shaking to an A600 of about 1-2 and then harvested by centrifugation.
  • DNA from the yeast cultures was extracted as described above, electrophoresed at 30 Volts and 30 mAmps for 10-15 hours into 0.8% agarose gels, transferred to nitrocellulose and hybridized to 32P-labelled pBR322 or pBR325 as described above.
  • a sample containing 10 ng of plasmid isolated from E. coli and a sample containing 1-2 ⁇ g of untransformed Pichia pastoris NRRL Y-15851 (GS115) DNA were electrophoresed in parallel with the experimental samples.
  • the labelled probe hybridized in a pattern identical to the plasmid DNA isolated from E. coli.
  • the labelled probe was found to hybridize to high molecular weight chromosomal DNA from Pichia pastoris NRRL Y-15851 (GS115) when transformed with pYJ8 ⁇ Cla (an integrative transforming vector which has no ARS activity in Pichia ). Probe did not hybridize to DNA from untransformed NRRL Y-15851.
  • An average plasmid copy number per P. pastoris cell was derived from the ratio of the amount of the genomic copy of the P. pastoris HIS4 gene to that of a plasmid-borne HIS4 gene. Since the strains examined contained plasmids with the Pichia HIS4 gene, DNAs were extracted, digested with restriction endonucleases, electrophoresed into an agarose gel, transferred to a nitrocellulose filter and hybridized with a 32P-labelled 2.7 kbp Bgl II fragment containing the Pichia HIS4 gene.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
  • Peptides Or Proteins (AREA)
  • Alcoholic Beverages (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Claims (14)

  1. Fragment d'ADN provenant de Pichia pastoris comprenant une séquence de réplication autonome (SRAP) dans lequel ce fragment d'ADN peut maintenir un plasmide en tant qu'élément extrachromosomique sous forme de copies multiples par cellule dans Pichia pastoris; et dans lequel ce fragment d'ADN provoque une augmentation de fréquence de la transformation de Pichia pastoris avec un vecteur contenant ce fragment d'ADN comparé à la fréquence de tranformation de Pichia pastoris avec un vecteur qui ne contient pas ce fragment d'ADN; dans lequel
    (a) ce fragment d'ADN est identifié comme indiqué par la carte de restriction dans la Fig. 1 des schémas (SRAP1) ou
    (b) ce fragment d'ADN est identifié comme indiqué par la carte de restriction dans la Fig. 2 des schémas (SRAP2)
  2. Fragment d'ADN selon la revendication 1 caractérisé en ce que cette séquence de réplication autonome provient de Pichia pastoris NRRL Y-11430.
  3. Plasmide hybride capable de transformer Pichia pastoris dans lequel ce plasmide comprend la séquence de réplication autonome de la revendication 1 et dans lequel ce plasmide est maintenu en tant qu'élément extrachromosomique dans Pichia pastoris.
  4. Plasmide hybride selon la revendication 3 dans lequel ce plasmide est caractérisé comme indiqué par la carte de restriction de la Fig. 7 des schémas (pYJ30).
  5. Plasmide hybride selon la revendication 3 dans lequel ce plasmide est caractérisé comme indiqué par la carte de restriction de la figure 8 des schémas (pYJ32).
  6. Souche de levure transformée provenant de Pichia pastoris ayant été obtenue en transformant Pichia pastoris avec le plasmide hybride de l'une quelconque des revendications 3 à 7.
  7. Escherichia coli NRRL B-15890 (LE392-pYJ30).
  8. Escherichia coli NRRL B-15891 (LE392-pYJ32).
  9. Procédé de préparation d'un fragment d'ADN selon la revendication 1 comprenant:
    (a) la culture d'Escherichia coli NRRL B-15890 (LE392-pYJ30) dans un milieu nutritif
    (b) la rupture des cellules cultivées; et
    (c) la récupération d'un plasmide identifié comme indiqué par la carte de restriction de la Fig.7 des schémas et ayant une taille de 7.1 kpb (pYJ30) à partir des cellules rompues.
    ou
    (a) la culture d'Escherichia coli NRRL B-15891 (LE392-pYJ32) dans un milieu nutritif
    (b) la rupture des cellules cultivées; et
    (c) la récupération d'un plasmide identifié comme indiqué par la carte de restriction dans la Fig.8 des schémas et ayant une taille de 7.3 kpb (pYJ32) à partir des cellules rompues.
  10. Procédé selon la revendication 9 comprenant en plus:
    (d) la digestion de ce plasmide identifié comme indiqué par la carte de restriction dans la Fig.7 des schémas et ayant une taille de 7.1 kpb (pYJ30) avec l'une des associations d'enzymes de restriction choisies dans le groupe comprenant:
    EcoRI-HindIII, et
    TaqI;
    (e) la récupération d'un fragment d'ADN caractérisé par la carte de restriction de la Fig.1 des schémas (SRAP1)
    ou
    (d) la digestion de ce plasmide identifié comme indiqué par la carte de restriction dans la Fig.8 des schémas et ayant une taille de 7.3 kpb (pYJ32) avec l'une des associations d'enzymes de restriction choisies dans le groupe comprenant:
    EcoRI-HindIII,
    ClaI-HindIII, et
    TaqI;
    (e) la récupération d'un fragment d'ADN caractérisé par la carte de restriction de la Fig.1 des schémas (SRAP2).
  11. Procédé d'isolement de séquences d'ADN de Pichia pastoris selon la revendication 1, ce procédé comprenant:
    (a) la digestion partielle d'ADN de Pichia pastoris par une enzyme de restriction; la préparation d'une bibliothèque de fragments d'ADN dans un vecteur; dans lequel ce vecteur comprend:
    (i) un gène marqueur; dans lequel ce gène marqueur comprend un gène fonctionnel qui confère un phénotype sélectionnable de Pichia pastoris.
    (ii) des séquences bactériennes permettant la transformation des bactéries par ce vecteur, l'amplification de ce vecteur dans un hôte bactérien et la sélection d'un hôte bactérien transformé, mais
    (iii) aucune activité de réplication autonome de la levure;
    (b) la transformation de Pichia pastoris par cette bibliothèque; dans lequel ce gène marqueur peut être sélectionné dans Pichia pastoris;
    (c) le recueil des colonies transformées produites dans l'étape (b) et leur culture dans des conditions sélectives;
    (d) l'extraction de l'ADN total des cellules qui survivent aux conditions de croissance sélective;
    (e) la transformation de cellules de E. coli compétent avec l'ADN total obtenu dans l'étape (d);
    (f) la culture des cellules de E. coli transformé obtenues dans l'étape (e) dans des conditions de culture sélectives, dans lequel ces conditions de culture sélectives comprennent des milieux avec antibiotiques auxquels ces séquences bactériennes fournissent une résistance;
    (g) la récupération du plasmide de ces cellules de E. coli transformé;
    (h) la transformation de Pichia pastoris avec le plasmide récupéré dans l'étape (g);
    (i) la culture de Pichia pastoris transformé obtenu dans l'étape (h) dans des conditions de culture sélectives;
    (j) la sélection et la purification de colonies qui cultivent bien dans les conditions de culture sélectives de l'étape (i);
    (k) le transfert des colonies purifiées dans un liquide de culture et la culture dans des conditions de culture sélectives;
    (l) l'extraction de l'ADN total de cultures cultivées dans une culture liquide;
    (m) la transformation de cellules de E. coli compétent avec l'ADN isolé dans l'étape (l);
    (n) la sélection des colonies qui donnent la fréquence de transformation la plus élevée de E. coli dans l'étape (m);
    (o) la récupération de plasmides à partir de colonies choisies dans l'étape (n); et
    (p) le prélèvement et la caractérisation du fragment d'ADN inséré contenu dans le plasmide récupéré dans l'étape (o) par des cartes de restriction; et
    (q) sélection de fragments d'ADN ayant les caractéristiques définies dans la revendication 1.
  12. Procédé selon la revendication 11 caractérisé en ce que ce vecteur est le mutant auxotrophe de Pichia pastoris NRRL Y-15851 (GS 115).
  13. Procédé selon la revendication 11 caractérisé en ce que ce vecteur est identifié comme indiqué par la carte de restriction de la fig. 5 des schémas et possède une taille de 10,5 kbp (pYJ8ΔCla)
  14. Procédé selon la revendication 11 caractérisé en ce que ce vecteur est identifié comme indiqué par la carte de restriction de la fig. 6 des schémas et possède une taille de 7,0 kbp (pY114).
EP85113735A 1984-10-30 1985-10-29 Séquences à réplication autonome pour des souches de levure du genre Pichia Expired - Lifetime EP0180899B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT85113735T ATE71660T1 (de) 1984-10-30 1985-10-29 Autonome replikationssequenzen fuer hefestaemme des genus pichia.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US666577 1984-10-30
US06/666,577 US4837148A (en) 1984-10-30 1984-10-30 Autonomous replication sequences for yeast strains of the genus pichia

Publications (3)

Publication Number Publication Date
EP0180899A2 EP0180899A2 (fr) 1986-05-14
EP0180899A3 EP0180899A3 (en) 1987-09-23
EP0180899B1 true EP0180899B1 (fr) 1992-01-15

Family

ID=24674597

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85113735A Expired - Lifetime EP0180899B1 (fr) 1984-10-30 1985-10-29 Séquences à réplication autonome pour des souches de levure du genre Pichia

Country Status (18)

Country Link
US (1) US4837148A (fr)
EP (1) EP0180899B1 (fr)
JP (2) JPH0795955B2 (fr)
AT (1) ATE71660T1 (fr)
AU (1) AU563860B2 (fr)
CA (1) CA1273882C (fr)
DE (1) DE3585206D1 (fr)
DK (1) DK496185A (fr)
ES (1) ES8609463A1 (fr)
FI (1) FI94426C (fr)
GR (1) GR852607B (fr)
IE (1) IE58216B1 (fr)
IL (1) IL76762A (fr)
MX (1) MX429A (fr)
NO (1) NO177269C (fr)
PT (1) PT81400B (fr)
SG (1) SG43192G (fr)
ZA (1) ZA858183B (fr)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) * 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4996144A (en) * 1985-01-25 1991-02-26 Calgene, Inc. Microassay for detection of DNA and RNA
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
IL81817A0 (en) * 1986-03-14 1987-10-20 Phillips Petroleum Co Methanol and glucose responsive yeast regulatory regions
FR2626584B1 (fr) * 1988-01-28 1990-07-13 Agronomique Inst Nat Rech Sequence ars efficace chez yarrowia lipolytica et procede pour sa preparation
IL89992A0 (en) 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human serum albumin in methylotrophic yeasts
JP2596466B2 (ja) * 1990-03-03 1997-04-02 アサヒビール株式会社 ダニの主要アレルゲンの還伝情報を有するｄｎａおよび該アレルゲンの製造方法
US6197548B1 (en) 1990-04-02 2001-03-06 Medeva Pharma Limited Transformed Pichia expressing the pertactin antigen
US5369028A (en) * 1990-04-03 1994-11-29 The Salk Institute Biotechnology/Industrial Associates, Inc. DNA and mRNA encoding human neuronal nicotinic acetylcholine receptor compositions and cells transformed with same
US6440681B1 (en) 1990-04-03 2002-08-27 Merck & Co., Inc. Methods for identifying agonists and antagonists for human neuronal nicotinic acetylcholine receptors
US5258302A (en) * 1990-07-03 1993-11-02 The Salk Institute Biotechnology/Industrial Associates, Inc. DNA for expression of aprotinin in methylotrophic yeast cells
JPH06500470A (ja) * 1990-09-04 1994-01-20 メルク　エンド　カンパニー　インコーポレーテッド メチロトローフ酵母細胞におけるインスリン様成長因子の産生
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
JP4236698B2 (ja) 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
WO1992013951A1 (fr) * 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production de serumalbumine humaine dans des cellules de levure methylotrophique
AU661844B2 (en) * 1991-04-01 1995-08-10 Merck Sharp & Dohme Corp. Genes which influence (pichia) proteolytic activity, and uses therefor
CA2058820C (fr) * 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Cassettes d'expression et vecteurs pour la secretion de serum albumine humaine dans des cellules pichia pastoris
US5330901A (en) * 1991-04-26 1994-07-19 Research Corporation Technologies, Inc. Expression of human serum albumin in Pichia pastoris
US5665600A (en) * 1991-09-18 1997-09-09 Research Corporation Technologies, Inc. Pichia pastoris linear plasmids and DNA fragments thereof
EP0688361B1 (fr) * 1993-03-08 2004-10-13 Merck & Co., Inc. Compositions de recepteurs neuronaux humains de l'acetylcholine nicotinique et procedes faisant appel a ces compositions
EP0696320B1 (fr) * 1993-04-20 2002-09-25 Merck & Co., Inc. Sous-unites receptrices du n-methyl-d-aspartate humain, acides nucleiques codant pour elles, et leur utilisation
US6001581A (en) 1993-06-04 1999-12-14 Sibia Neurosciences, Inc. Cation-based bioassay using human metabotropic glutamate receptors
US5521297A (en) 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
US5912122A (en) * 1993-06-04 1999-06-15 Sibia Neurosciences, Inc. Nucleic acids encoding and method for detecting nucleic acid encoding human metabotropic glutamate receptor subtype mGluR6
US6638905B2 (en) * 1993-06-18 2003-10-28 The Salk Institute For Biological Studies Cloning and recombinant production of CFR receptor(s)
US6495343B1 (en) 1993-06-18 2002-12-17 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
GB2287941B (en) * 1993-11-08 1998-01-28 Salk Inst Biotech Ind Human alpha2 neuronal nicotinic acetylcholine receptor compositions and methods employing same
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5863894A (en) * 1995-06-05 1999-01-26 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5866543A (en) * 1995-06-05 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5945275A (en) * 1994-10-18 1999-08-31 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5872098A (en) * 1995-06-05 1999-02-16 Corvas International, Inc. Nematode-extracted anticoagulant protein
CA2202351A1 (fr) * 1994-10-18 1996-04-25 George Phillip Vlasuk Proteines anticoagulantes et inhibiteurs de la serine-protease extraits de nematodes
AU711405B2 (en) * 1994-10-18 1999-10-14 Dendreon Corporation Nematode-extracted serine protease inhibitors and anticoagulant proteins
US6485967B1 (en) 1995-06-07 2002-11-26 Merck & Co., Inc. Human neuronal nicotinic acetylcholine receptor α6 and β3 nucleic acid
MX9605082A (es) 1996-10-24 1998-04-30 Univ Autonoma De Nuevo Leon Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano.
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
ATE505478T1 (de) 1997-08-27 2011-04-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkalen b epitopen
DE69841807D1 (de) 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic Neisseriale antigene
SG123535A1 (en) 1998-01-14 2006-07-26 Chiron Srl Neisseria meningitidis antigens
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
NZ508366A (en) 1998-05-01 2004-03-26 Chiron Corp Neisseria meningitidis antigens and compositions
EP1121437B1 (fr) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Genes regules dans les cellules du cancer du sein metastatique et du cancer du colon
EP1961813B1 (fr) 1998-12-16 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Kinase de type humain dépendant de la cycline (hPNQALRE)
US6780615B1 (en) 1998-12-31 2004-08-24 Genway Biotech Inc. Production of recombinant monellin using methylotrophic yeast expression system
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US7504253B2 (en) * 1999-06-11 2009-03-17 The Burnham Institute For Medical Research Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
US6261820B1 (en) * 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
EP1305412A2 (fr) 1999-10-14 2003-05-02 Clontech Laboratories Inc. Chromo/fluoro-proteines derivees d'anthozoa et methodes d'utilisation
US8734812B1 (en) 1999-10-29 2014-05-27 Novartis Ag Neisserial antigenic peptides
US7033776B2 (en) * 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
EP1248841B1 (fr) 2000-01-10 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Genes exprimes de maniere differentielle dans le cancer du sein
PT1248647E (pt) 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
US8697394B2 (en) * 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7863020B2 (en) * 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
EP2322644A1 (fr) 2000-06-28 2011-05-18 GlycoFi, Inc. Procédé de production de glycoprotéines modifiées
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7625756B2 (en) * 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
JP4092194B2 (ja) 2000-06-30 2008-05-28 フランダース インターユニバーシティ インスティテュート フォア バイオテクノロジー （ヴィーアイビー） ピキアパストリス（ＰｉｃｈｉａＰａｓｔｏｒｉｓ）におけるタンパク質糖鎖修飾
DE60136379D1 (de) * 2000-07-14 2008-12-11 Archer Daniels Midland Co Transformationssysteme für flavinogene hefen
US7009045B2 (en) * 2000-07-14 2006-03-07 Archer-Daniels-Midland Company Transformation systems for flavinogenic yeast
EP2189473A3 (fr) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
WO2002059337A1 (fr) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Gène anti-apoptotique scc-s2 et ses utilisations diagnostiques et thérapeutiques
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002081640A2 (fr) * 2001-04-06 2002-10-17 Georgetown University Gene shinc-1 et ses utilisations diagnostiques et therapeutiques
AU2002305151A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081642A2 (fr) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 et ses utilisations diagnostiques et therapeutiques
EP2335724A1 (fr) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation contre la Chlamydia trachomatis
ES2329666T3 (es) * 2001-12-19 2009-11-30 The University Of Chicago Proteinas fluorescentes de maduracion rapida y procedimientos de uso de las mismas.
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US20060088834A1 (en) * 2002-04-15 2006-04-27 Gretchen Bain Matrix analysis of gene expression in cells (magec)
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
AU2003239863A1 (en) * 2002-05-24 2003-12-12 Restoragen Inc. Method for enzymatic production of glp-1 (7-36) amide peptides
CA2485829A1 (fr) 2002-05-24 2003-12-04 Peng Luan Procedes et constructions destines a l'expression a haut rendement de la clostripaine
EP1554302A4 (fr) * 2002-05-24 2006-05-03 Restoragen Inc Procedes et produits de recombinaison d'adn pour production a haut rendement de polypeptides
EP1513945A4 (fr) * 2002-05-24 2008-12-24 Restoragen Inc Methode de production enzymatique universelle de peptides bioactifs
AU2003243316A1 (en) * 2002-05-24 2003-12-12 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
IL165717A0 (en) 2002-06-26 2006-01-15 Flanders Interuniversity Inst A strain of methylotrophic yeast for producing proteins
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
DE60335602D1 (de) * 2002-12-18 2011-02-17 Roche Diagnostics Gmbh Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
DE60319333D1 (de) * 2002-12-20 2008-04-10 Roche Diagnostics Gmbh Hitzelabile Desoxyribonuklease I-Varianten
US7332299B2 (en) * 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
EP1460425A1 (fr) * 2003-03-17 2004-09-22 Boehringer Mannheim Gmbh Enzymes déglycosylés pour conjugués
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
AU2004263900A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
US20070274988A1 (en) * 2003-10-10 2007-11-29 Five Prime Therapeautics, Inc. Kiaa0779, Splice Variants Thereof, and Methods of Their Use
AU2004290587B2 (en) * 2003-11-14 2010-08-12 Arriva Pharmaceuticals, Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
ME01366B (fr) * 2003-11-21 2013-12-20 Nps Allelix Corp Production de peptides 2 de type glucagon et de leurs analogues
CA2486195C (fr) * 2003-12-05 2012-03-06 Stephan Glaser Carboxypeptidase b exprimee par ecombinaison et sa purification
WO2005074546A2 (fr) 2004-02-02 2005-08-18 Ambrx, Inc. Polypeptides d'hormone de croissance humaine modifies et utilisations
WO2005086915A2 (fr) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Traitement de la bronchopneumopathie chronique obstructive par inhalation a faible dose d'inhibiteur de protease
CA2561696C (fr) 2004-03-29 2013-09-03 Galpharma Co., Ltd. Proteine de modification de galectine-9 novatrice et utilisation de celle-ci
US7250298B2 (en) * 2004-04-07 2007-07-31 The University Of Chicago Monomeric red fluorescent proteins
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US7638299B2 (en) * 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
CN101087875B (zh) * 2004-12-22 2012-08-22 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
NZ555206A (en) 2004-12-22 2010-09-30 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
DK1828224T3 (en) 2004-12-22 2016-07-18 Ambrx Inc Compositions containing, methods including, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
US7816320B2 (en) * 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
AU2006227254B2 (en) 2005-03-21 2011-09-01 Quest Diagnostics Investments Llc Alpha ketoamide compounds as cysteine protease inhibitors
EP3214095B1 (fr) 2005-05-12 2019-12-11 ZymoGenetics, Inc. Compositions et procédés pour moduler les réponses immunologiques
CA2609205A1 (fr) * 2005-06-03 2006-12-14 Ambrx, Inc. Molecules d'interferons humains ameliorees et utilisations de celles-ci
NZ565294A (en) * 2005-08-18 2010-06-25 Ambrx Inc Compositions of tRNA and uses thereof
US7981635B2 (en) * 2005-09-14 2011-07-19 Sanofi-Aventis Deutschland Gmbh Cleavage of precursors of insulins by a variant of trypsin
WO2007053732A2 (fr) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Polymorphismes des promoteurs du gene blys et leur utilisation dans des procedes de diagnostic
WO2007056448A2 (fr) * 2005-11-08 2007-05-18 Ambrx, Inc. Accelerateurs destines a la modification d’acides amines non-naturels et de polypeptides formes d'acides amines non-naturels
PT2339014E (pt) * 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
NZ595303A (en) * 2005-12-14 2013-03-28 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
NZ574960A (en) * 2006-09-08 2012-02-24 Ambrx Inc Suppressor trna transcription in vertebrate cells
EP2061878B1 (fr) * 2006-09-08 2014-01-08 Ambrx, Inc. Arnt suppresseur hybride pour cellules de vertébrés
DK2615108T3 (en) 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
JP5967861B2 (ja) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
US8114630B2 (en) * 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EA201000343A1 (ru) 2007-10-04 2011-10-31 Займодженетикс, Инк. ЧЛЕН СЕМЕЙСТВА B7, zB7H6 И РОДСТВЕННЫЕ КОМПОЗИЦИИ И СПОСОБЫ
WO2009059305A2 (fr) * 2007-11-01 2009-05-07 The University Of Chicago Protéines fluorescentes rouges avec expression bactérienne amplifiée, luminosité accrue et agrégation réduite
NZ584825A (en) * 2007-11-20 2013-03-28 Ambrx Inc Modified insulin polypeptides and their uses
WO2009073511A2 (fr) * 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphismes du gène blys et utilisation dans des procédés diagnostiques
EP3103880A1 (fr) 2008-02-08 2016-12-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
WO2009114093A2 (fr) 2008-03-03 2009-09-17 Abbott Laboratories Procédés pour transformer des levures
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
PL2337846T3 (pl) 2008-09-26 2018-06-29 Ambrx, Inc. Mikroorganizmy i szczepionki z replikacją zależną od nie-naturalnych aminokwasów
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
JP5990102B2 (ja) 2009-09-29 2016-09-07 ユニフェルシテイト ヘント ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解
US20130053550A1 (en) 2009-11-19 2013-02-28 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
CA2784793A1 (fr) 2009-12-21 2011-07-21 Ambrx, Inc. Polypeptides modifies de la somatotropine bovine et leurs utilisations
KR20120123365A (ko) 2009-12-21 2012-11-08 암브룩스, 인코포레이티드 변형된 돼지 소마토트로핀 폴리펩티드 및 이의 용도
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
US8617856B2 (en) * 2010-01-07 2013-12-31 Wisconsin Alumni Research Foundation Fatty acid-producing hosts
FI3572091T3 (fi) 2010-08-17 2024-03-01 Ambrx Inc Muokattuja relaksiinipolypeptidejä ja niiden käyttötapoja
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
JP6131190B2 (ja) 2010-09-29 2017-05-17 オキシレイン ユーケー リミテッド リン酸化ｎ−グリカンの脱マンノシル化
SG189108A1 (en) 2010-09-29 2013-05-31 Oxyrane Uk Ltd Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
AU2013234042B2 (en) 2012-03-15 2017-11-02 Oxyrane Uk Limited Methods and materials for treatment of Pompe's disease
US20140073022A1 (en) 2012-09-10 2014-03-13 Wisconsin Alumni Research Foundation Production of polyhydroxyalkanoates with a defined composition from an unrelated carbon source
EP2959001B1 (fr) 2013-02-25 2017-04-19 University Of Washington Through Its Center For Commercialization Séquence à réplication autonome fonctionnant dans un large spectre de levures
US20190040368A1 (en) 2013-03-05 2019-02-07 Oxyrane Uk Limited Production of catalytically active type i sulfatase
AU2014234962C1 (en) 2013-03-21 2019-01-17 Evonik Operations Gmbh Purification of triple helical proteins
CN105764920B (zh) 2013-09-09 2020-07-24 联邦科学工业研究组织 修饰的细菌胶原蛋白样蛋白
US9708630B1 (en) 2013-10-08 2017-07-18 Wisconsin Alumni Research Foundation Cells and methods for producing fatty alcohols
WO2016065326A2 (fr) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Polypeptides fgf-21 modifiés et leurs utilisations
WO2016186948A1 (fr) 2015-05-15 2016-11-24 Albert Einstein College Of Medicine, Inc. Étiquettes de fusion dérivées de gfp pour l'expression de protéines
US10301653B2 (en) 2015-07-06 2019-05-28 Wisconsin Alumni Research Foundation Microorganisms that co-consume glucose with non-glucose carbohydrates and methods of use
US10421951B2 (en) 2016-06-22 2019-09-24 Wisconsin Alumni Research Foundation Gene construct encoding mutant thioesterase, mutant thioesterase encoded thereby, transformed host cell containing the gene construct, and method of using them to produce medium-chain fatty acids
SG11201907209QA (en) 2017-02-08 2019-09-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11603412B2 (en) 2017-10-25 2023-03-14 The Regents Of The University Of California Antibodies against CDCP1 for the treatment and detection of cancer
CN111378585B (zh) * 2018-12-28 2023-06-16 丰益(上海)生物技术研发中心有限公司 用于表达外源基因的毕赤酵母突变株
WO2021236919A1 (fr) 2020-05-20 2021-11-25 Wisconsin Alumni Research Foundation Cellules et procédés de production de méthylcétones
US20240218383A1 (en) 2021-05-12 2024-07-04 Circular Industries Holding Pte Ltd. Recombinant yeasts for producing acetone and/or isopropanol from fatty acid feedstocks

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2441659A1 (fr) * 1978-11-14 1980-06-13 Anvar Nouveaux plasmides hybrides et microorganismes les contenant
US4354535A (en) * 1980-04-21 1982-10-19 Powell Robert Y Hand-held automatic wire binding tool
US4617274A (en) * 1981-10-29 1986-10-14 Phillips Petroleum Company Biochemical conversions by yeast fermentation at high cell densities
IE55817B1 (en) * 1982-05-19 1991-01-30 Gist Brocades Nv Cloning system for kluyveromyces species
US4628033A (en) * 1983-10-06 1986-12-09 Pfizer Inc. Novel host strain for transformation of Yarrowia lipolytica

Also Published As

Publication number Publication date
JPH0795955B2 (ja) 1995-10-18
JP2552809B2 (ja) 1996-11-13
IE852472L (en) 1986-04-30
ES548304A0 (es) 1986-07-16
FI94426B (fi) 1995-05-31
JPH0686680A (ja) 1994-03-29
AU4875785A (en) 1986-06-12
PT81400A (en) 1985-11-01
US4837148A (en) 1989-06-06
NO177269B (no) 1995-05-08
PT81400B (pt) 1987-11-11
ATE71660T1 (de) 1992-02-15
FI854143A0 (fi) 1985-10-23
IE58216B1 (en) 1993-08-11
DK496185D0 (da) 1985-10-29
ZA858183B (en) 1987-03-25
DE3585206D1 (de) 1992-02-27
FI94426C (fi) 1995-09-11
CA1273882A (fr) 1990-09-11
NO854332L (no) 1986-05-02
IL76762A0 (en) 1986-02-28
NO177269C (no) 1995-08-16
DK496185A (da) 1986-05-01
FI854143L (fi) 1986-05-01
ES8609463A1 (es) 1986-07-16
JPS61108390A (ja) 1986-05-27
CA1273882C (fr) 1990-09-11
EP0180899A2 (fr) 1986-05-14
IL76762A (en) 1991-08-16
GR852607B (fr) 1986-03-04
AU563860B2 (en) 1987-07-23
EP0180899A3 (en) 1987-09-23
MX429A (es) 1993-11-01
SG43192G (en) 1992-06-12

Similar Documents

Publication Publication Date Title
EP0180899B1 (fr) Séquences à réplication autonome pour des souches de levure du genre Pichia
US4885242A (en) Genes from pichia histidine pathway and uses thereof
EP0183071B1 (fr) Région de régulation pour l'expression de gène hétérologue dans de la levure
EP0226752B1 (fr) Procédé pour une expression supérieure de polypeptides dans une levure du genre Pichia
EP0221455A1 (fr) Gène d'argininosuccinate lyase de Pichia pastoris et son utilisation
US4808537A (en) Methanol inducible genes obtained from pichia and methods of use
EP0495208B1 (fr) Gène de l'acide phosphatase de pichia pastoris
Kurtz et al. Integrative transformation of Candida albicans, using a cloned Candida ADE2 gene
EP0263311A2 (fr) Production du facteur de nécrose de tumeurs par des levures
JP2614314B2 (ja) メチロトロフィック酵母におけるＢ型肝炎ＳおよびｐｒｅＳ▲下２▼タンパク質の発現
EP0339567A1 (fr) Expression de protéine de PreS 2 de l'hépatite B en levures méthylotrophiques
EP0533153B1 (fr) Plasmides linéaires de Pichia pastoris et leurs fragments
EP0248227A1 (fr) Production de streptokinase à partir de cellules de levure
GB2188050A (en) pWS101 plasmid, method of obtaining same and use thereof
IE83234B1 (en) DNA fragment encoding an AOX

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19880224

17Q First examination report despatched

Effective date: 19891020

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 71660

Country of ref document: AT

Date of ref document: 19920215

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 3585206

Country of ref document: DE

Date of ref document: 19920227

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
EPTA Lu: last paid annual fee
REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: RESEARCH CORPORATION TECHNOLOGIES, INC.

ITPR It: changes in ownership of a european patent

Owner name: CESSIONE;RESEARCH CORPORATION TECHNOLOGIES, INC.

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

NLS Nl: assignments of ep-patents

Owner name: RESEARCH CORPORATION TECHNOLOGIES, INC. TE TUCSON,

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

EAL Se: european patent in force in sweden

Ref document number: 85113735.6

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20040914

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20040915

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20040921

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20041001

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20041004

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20041005

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20041029

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20041105

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20050107

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20051028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20051029

BE20 Be: patent expired

Owner name: *RESEARCH CORP. TECHNOLOGIES INC.(UNE SOCIETE CONS

Effective date: 20051029

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20051029

BE20 Be: patent expired

Owner name: *RESEARCH CORP. TECHNOLOGIES INC.(UNE SOCIETE CONS

Effective date: 20051029